Acorda Therapeutics, Inc. (NASDAQ:ACOR) – Analysts at Leerink Swann increased their Q2 2018 EPS estimates for Acorda Therapeutics in a research report issued to clients and investors on Wednesday. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will post earnings per share of $0.84 for the quarter, up from their prior estimate of $0.67. Leerink Swann has a “Market Perform” rating and a $18.00 price objective on the stock. Leerink Swann also issued estimates for Acorda Therapeutics’ Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.65) EPS, FY2018 earnings at $0.77 EPS and FY2019 earnings at ($2.18) EPS.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The business had revenue of $141.07 million during the quarter, compared to analyst estimates of $150.64 million. During the same quarter last year, the firm earned ($0.04) EPS. Acorda Therapeutics’s revenue for the quarter was up 4.0% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “Acorda Therapeutics, Inc. Expected to Earn Q2 2018 Earnings of $0.84 Per Share (ACOR)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/acorda-therapeutics-inc-expected-to-earn-q2-2018-earnings-of-0-84-per-share-acor/1711551.html.

Several other analysts have also recently weighed in on ACOR. Stifel Nicolaus reiterated a “buy” rating on shares of Acorda Therapeutics in a research note on Friday, July 28th. BidaskClub cut shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $18.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. Cowen and Company reiterated a “buy” rating and issued a $35.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. Finally, Janney Montgomery Scott reiterated a “hold” rating and issued a $18.00 price objective on shares of Acorda Therapeutics in a research note on Wednesday, August 30th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $21.51.

Shares of Acorda Therapeutics (NASDAQ ACOR) opened at $17.80 on Friday. Acorda Therapeutics has a 12 month low of $13.60 and a 12 month high of $33.00. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49.

In other news, major shareholder Scopia Capital Management Lp bought 766,201 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was bought at an average cost of $19.23 per share, for a total transaction of $14,734,045.23. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 7.90% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in ACOR. State Street Corp increased its position in Acorda Therapeutics by 52.4% during the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after purchasing an additional 851,290 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Acorda Therapeutics by 29.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock worth $46,745,000 after purchasing an additional 541,418 shares in the last quarter. RA Capital Management LLC increased its position in Acorda Therapeutics by 83.8% during the 2nd quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock worth $17,735,000 after purchasing an additional 410,431 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Acorda Therapeutics by 306.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock worth $10,538,000 after purchasing an additional 403,467 shares in the last quarter. Finally, Northern Trust Corp increased its position in Acorda Therapeutics by 65.2% during the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock worth $17,690,000 after purchasing an additional 354,304 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.